title: A randomized crossover study to evaluate Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence.
abstract: OBJECTIVE
  To investigate the potential therapeutic benefits of the selective alpha1A/1l-adrenoceptor partial agonist Ro 115-1240 in women with mild-to-moderate stress urinary incontinence (SUI).
  
  
  METHODS
  Thirty-seven women with mild-to-moderate SUI were enrolled in a randomized, placebo-controlled crossover study. Patients received 1.5 mg Ro 115-1240 twice daily or matching placebo for 2 or 4 weeks. Voiding diaries were used to record the number of SUI episodes, urge incontinence episodes and pads used. Sitting blood pressures and heart rate were recorded at each visit.
  
  
  RESULTS
  Ro 115-1240 was associated with a significantly lower mean weekly number of SUI episodes than placebo (8.4 vs 6.0; P= 0.0079), a 28% relative improvement over placebo. There was also a significantly lower mean number of pads used and wet pads changed/week with Ro 115-1240 than with placebo (P = 0.0055 and 0.0066, respectively). The most frequently reported treatment-emergent adverse events were scalp tingling, headache, chills, piloerection, and pruritus. Generally these events were transient and mild to moderate. There was a slightly lower mean sitting heart rate with Ro 115-1240 than with placebo, but no difference in mean systolic or diastolic blood pressure between treatments.
  
  
  CONCLUSIONS
  This study suggests that selective alpha1A/1l-adrenoceptor partial agonists have the potential to improve the symptoms of SUI with little or no cardiovascular effect. These results are encouraging and a randomized controlled trial of Ro 115-1240 in a larger population with SUI is warranted to substantiate these findings.
authors.affiliation: Hoffmann-La Roche, Inc., Nutley, NJ, USA. david.musselman@roche.com
authors.forename: D M
authors.initials: DM
authors.lastname: Musselman
authors.forename: A P D W
authors.initials: AP
authors.lastname: Ford
authors.forename: D J
authors.initials: DJ
authors.lastname: Gennevois
authors.forename: M L
authors.initials: ML
authors.lastname: Harbison
authors.forename: A L
authors.initials: AL
authors.lastname: Laurent
authors.forename: A S
authors.initials: AS
authors.lastname: Mokatrin
authors.forename: R R
authors.initials: RR
authors.lastname: Stoltz
authors.forename: D R
authors.initials: DR
authors.lastname: Blue
mesh_terms: D000293:Adolescent; D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008875:Middle Aged; D013449:Sulfonamides / Q000627:therapeutic use; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
chemical_list: D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D007093:Imidazoles; D013449:Sulfonamides; C481520:dabuzalgron